As an example, in a phase II trial of patients with NSCLC with untreated brain metastases 11 of 37 (30%) patients with PD-L1-positive tumors experienced objective CNS responses with pembrolizumab whereas that number was 0 out of 5 (0%) in those with PD-L1-negative tumors [62]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.